Next Article in Journal
Comprehensive Characterization of Reference Standard Lots of HIV-1 Subtype C Gp120 Proteins for Clinical Trials in Southern African Regions
Previous Article in Journal
Coupling Peptide Antigens to Virus-Like Particles or to Protein Carriers Influences the Th1/Th2 Polarity of the Resulting Immune Response
Article

A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex

1
National Reference Centre Bordetella and Toxigenic Corynebacteria, Service Immunology, Scientific Institute of Public Health (WIV-ISP, Site Ukkel), 1180 Brussels, Belgium
2
National Reference Centre Bordetella and Toxigenic Corynebacteria, University Hospital VUB, UZ Brussels, 1090 Jette, Belgium
*
Author to whom correspondence should be addressed.
Academic Editor: Diane M. Harper
Vaccines 2016, 4(2), 16; https://doi.org/10.3390/vaccines4020016
Received: 24 December 2015 / Revised: 24 March 2016 / Accepted: 25 April 2016 / Published: 10 May 2016
Serosurveillance and seroprevalence studies are an essential tool to monitor vaccine-preventable diseases. We have developed a magnetic bead-based pentaplex immunoassay (MIA) for the simultaneous detection of IgG antibodies against diphtheria toxin (DT), tetanus toxin (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (Prn). The in-house pentaplex MIA showed a good correlation with commercial ELISAs with correlation coefficients between 0.89 for PT and 0.98 for TT. Intra- and inter-assay variability was <10%. A total of 670 anonymized serum samples collected in 2012 in Belgian adults (ages 20–29.9 years) were analyzed. Geometric mean concentrations (GMC) were 0.2 (0.13–0.29) IU/mL for DT, 0.63 (0.45–0.82) IU/mL for TT, 3.9 (2.6–5.8) IU/mL for PT, 16.3 (11.7–22.7) IU/mL for FHA and 15.4 (10.1–23.6) IU/mL for Prn. Antibody concentrations were below the protective level of 0.1 IU/mL in 26.4% of the sera for DT and in 8.6% of the sera for TT. Anti-PT IgG concentrations indicative of recent pertussis infection (>125 IU/mL) were detected in 1.2% of the subjects. High anti-PT antibodies were not correlated with high antibodies against any of the four other vaccine antigens. This pentaplex MIA will be used for a new large-scale Belgian serosurveillance/seroprevalence study of diphtheria, tetanus and pertussis. View Full-Text
Keywords: seroprevalence; serosurveillance; pertussis; diphtheria; tetanus; multiplex seroprevalence; serosurveillance; pertussis; diphtheria; tetanus; multiplex
Show Figures

Figure 1

MDPI and ACS Style

Caboré, R.N.; Piérard, D.; Huygen, K. A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. Vaccines 2016, 4, 16. https://doi.org/10.3390/vaccines4020016

AMA Style

Caboré RN, Piérard D, Huygen K. A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex. Vaccines. 2016; 4(2):16. https://doi.org/10.3390/vaccines4020016

Chicago/Turabian Style

Caboré, Raissa N., Denis Piérard, and Kris Huygen. 2016. "A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex" Vaccines 4, no. 2: 16. https://doi.org/10.3390/vaccines4020016

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop